The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Self-citationPujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Self-citationRethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Self-citationLedermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationAghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Self-citationGelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Self-citationFong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Self-citationGourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
Financial toxicity, Part I: a new name for a growing problem.
Zafar, S. Y., & Abernethy, A. P. (2013) · PubMed · Cited by 499
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Broglio, K. R., & Berry, D. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp369 · Cited by 491
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
Stuart, G. C. E., Kitchener, H., Bacon, M., duBois, A., Friedlander, M., Ledermann, J., Marth, C., Thigpen, T., & Trimble, E. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821b2568 · Cited by 425
Self-citationTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395 · cited 1×
“In patients unable to receive platinum with a longer TFIp, combination therapy may include doublet chemotherapy with non-platinum agents [24].”
Self-citationMinireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Clinical Trials in Recurrent Ovarian Cancer
Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb8aa · Cited by 224
Self-citationOutcomes and endpoints in trials of cancer treatment: the past, present, and future
Wilson, M. K., Karakasis, K., & Oza, A. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70375-4 · Cited by 219
Self-citationRegulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Downing, N. S., Aminawung, J. A., Shah, N. D., Braunstein, J. B., Krumholz, H. M., & Ross, J. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmsa1200223 · Cited by 176
Ang, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 141
Self-citationLortholary, A. H., Largillier, R., Weber, B. E., Gladieff, L., Alexandre, J., Durando, X., Slama, B., Dauba, J., Paraiso, D., & Pujade-Lauraine, É. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr149 · Cited by 91
Matulonis, U. A., Oza, A. M., Ho, T. W., & Ledermann, J. A. (2014) · Cancer · doi:10.1002/cncr.29082 · Cited by 87
Self-citationHurteau, J. A., Brady, M. F., Darcy, K. M., McGuire, W. P., Edmonds, P. R., Pearl, M. L., Ivanov, I., Tewari, K. S., Mannel, R. S., Zanotti, K. M., et al. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.08.002 · Cited by 73
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
Herzog, T. J., Armstrong, D. K., Brady, M. F., Coleman, R. L., Einstein, M. H., Monk, B. J., Mannel, R. S., Thigpen, J. T., Umpierre, S. A., Villella, J., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.008 · Cited by 72
Bruchim, I., Altaras, M. M., & Fishman, A. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6759 · Cited by 71
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
Sherrill, B. H., Kaye, J. A., Sandin, Cappelleri, & Chen (2012) · OncoTargets and Therapy · doi:10.2147/ott.s36683 · Cited by 49
Brundage, M., Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N. S., Pignata, S., Ferrero, A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr583 · Cited by 46
Self-citationLee, C. K., Simes, R. J., Brown, C. S. B., Gebski, V., Pfisterer, J., Swart, A. M., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds538 · Cited by 43
Self-citationDevelopment of the Measure of Ovarian Symptoms and Treatment Concerns
King, M. T., Stockler, M. R., Butow, P. N., O’Connell, R. L., Voysey, M., Oza, A. M., Gillies, K., Donovan, H. S., Mercieca‐Bebber, R., Martyn, J. K., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000167 · Cited by 40
Self-citationPrevis, R. A., Bevis, K. S., Huh, W. K., Tillmanns, T. D., Perry, L., Moore, K. N., Chapman, J. S., McClung, C., Kiet, T. K., Java, J., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.01.036 · Cited by 29
Patient-reported outcomes in ovarian cancer clinical trials
Friedlander, M. L., & King, M. T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt474 · Cited by 28
Self-citationComparison of oncology drug approval between Health Canada and the US Food and Drug Administration
Ezeife, D. A., Truong, T. H., Heng, D. Y. C., Bourque, S., Welch, S. A., & Tang, P. A. (2015) · Cancer · doi:10.1002/cncr.29246 · Cited by 25
Update of randomized trials in recurrent disease
Pujade-Lauraine, É., & Alexandre, J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr518 · Cited by 24
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Self-citationPujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Self-citationEpithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Self-citationColombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Self-citationDiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01549 · Cited by 511
“It is difficult to demonstrate improvements in OS in ovarian cancer trials because of the number and variety of uncontrolled postprogression treatment options including experimental agents.(10,11) In this descriptive OS analysis, more than 40% of placebo patients (v 14.”
BackgroundSelf-citation
Metadata
- Authors
- Wilson, M. K., Pujade-Lauraine, E., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S.-J., Ferrero, A. M., Edmondson, R. J., Wimberger, P., Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G., & Ochiai, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 28
- Issue
- 4
- Pages
- 727-732
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2560862072
- Cited by
- 289
- References
- 36
- FWCI
- 24.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.